Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Stable treatment with Oral Anti-Diabetic Drugs (metformin, sulphonylurea or a combination of both) for at least 3 months at the discretion of the Investigator~* HbA1C equal to or greater than 7.0% and equal to or lower than 11.0%~* Body Mass Index (BMI) equal to or lower than 45.0 kg/m2~Exclusion Criteria:~* Previous treatment with insulin~* Treatment with any anti-diabetic drug other than metformin and sulphonylurea~* Any previous exposure to exenatide or liraglutide~* Impaired liver or/and renal function~* History of any significant cardiac events~* Known retinopathy or maculopathy requiring acute treatment~* Recurrent major hypoglycaemia or hypoglycaemic unawareness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide 1.8 mg once daily + subject's own OAD treatment
- Exenatide (Type: ACTIVE_COMPARATOR): Exenatide 10 mcg twice daily + subject's own OAD treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).